The last five years have been exceptionally busy in terms of oncology drug development. Two interesting articles that reflect back on this period of time were recently published. The first, which I consider here, is “Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs” by Drs. Sham Mailankody and Vinay Prasad (JAMA Oncol. 2015; 1(4):539-540). This paper considers whether or not all of the recently approved cancer drugs merit their prices.

Back to News